Inozyme Pharma Inc (INZY)

$4.51

-0.07

(-1.53%)

Market is closed - opens 7 PM, 22 Apr 2024

Insights on Inozyme Pharma Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 48.4% return, outperforming this stock by 70.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 234.9% return, outperforming this stock by 309.9%

Performance

  • $4.38
    $4.63
    $4.51
    downward going graph

    2.88%

    Downside

    Day's Volatility :5.4%

    Upside

    2.59%

    downward going graph
  • $2.69
    $7.80
    $4.51
    downward going graph

    40.35%

    Downside

    52 Weeks Volatility :65.51%

    Upside

    42.18%

    downward going graph

Returns

PeriodInozyme Pharma IncSector (Health Care)Index (Russel 2000)
3 Months
0.45%
-0.4%
0.0%
6 Months
56.6%
8.5%
0.0%
1 Year
-21.57%
4.2%
-1.2%
3 Years
-75.04%
13.9%
-19.2%

Highlights

Market Capitalization
282.9M
Book Value
$2.27
Earnings Per Share (EPS)
-1.37
Wall Street Target Price
20.33
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-27.81%
Return On Equity TTM
-54.98%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-74.8M
Diluted Eps TTM
-1.37
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.5
EPS Estimate Next Year
-1.6
EPS Estimate Current Quarter
-0.32
EPS Estimate Next Quarter
-0.32

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Inozyme Pharma Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 350.78%

Current $4.51
Target $20.33

Technicals Summary

Sell

Neutral

Buy

Inozyme Pharma Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Inozyme Pharma Inc
Inozyme Pharma Inc
-23.69%
56.6%
-21.57%
-75.04%
-74.29%
Moderna, Inc.
Moderna, Inc.
-1.62%
26.13%
-28.15%
-35.32%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.25%
10.93%
12.37%
77.79%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-5.87%
27.44%
48.41%
234.91%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.33%
8.96%
19.79%
79.09%
133.97%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Inozyme Pharma Inc
Inozyme Pharma Inc
NA
NA
NA
-1.5
-0.55
-0.28
NA
2.27
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Inozyme Pharma Inc
Inozyme Pharma Inc
Buy
$282.9M
-74.29%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
133.97%
28.33
36.68%

Institutional Holdings

  • Adage Capital Partners Gp LLC

    8.96%
  • Pivotal bioVenture Partners Investment Advisor LLC

    7.28%
  • Sofinnova Ventures

    6.93%
  • Rock Springs Capital Management LP

    5.96%
  • Samlyn Capital, LLC

    5.46%
  • Eventide Asset Management, LLC

    5.15%

Corporate Announcements

  • Inozyme Pharma Inc Earnings

    Inozyme Pharma Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

we are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. our area of expertise is in disorders of paradoxical mineralization and our lead drug is an enzyme replacement therapy in pre-clinical development.

Organization
Inozyme Pharma Inc
Employees
59
CEO
Dr. Douglas A. Treco Ph.D.
Industry
Health Technology

FAQs